132 related articles for article (PubMed ID: 31177173)
21. Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I-II adenocarcinoma of the uterine cervix.
Huang XB; Zhang WW; Wu SG; Sun JY; He ZY; Zhou J
J Surg Oncol; 2018 Sep; 118(3):574-580. PubMed ID: 30114328
[TBL] [Abstract][Full Text] [Related]
22. [The expression of c-myc protein in uterine cervical cancer: a possible prognostic indicator].
Wu HJ
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Jul; 48(7):515-21. PubMed ID: 8754393
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for uterine cervical cancer.
Makino H; Kato H; Furui T; Morishige K; Kanematsu M
J Obstet Gynaecol Res; 2014 Apr; 40(4):1098-104. PubMed ID: 24320754
[TBL] [Abstract][Full Text] [Related]
24. Predictors of Radiation Field Failure After Definitive Chemoradiation in Patients With Locally Advanced Cervical Cancer.
Bae HS; Kim YJ; Lim MC; Seo SS; Park SY; Kang S; Kim SH; Kim JY
Int J Gynecol Cancer; 2016 May; 26(4):737-42. PubMed ID: 26937749
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
[TBL] [Abstract][Full Text] [Related]
26. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
28. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
30. Special AT-rich sequence-binding protein 1: a novel biomarker predicting cervical squamous cell carcinoma prognosis and lymph node metastasis.
Wang S; Wang L; Zhang Y; Liu Y; Meng F; Ma J; Shang P; Gao Y; Huang Q; Chen X
Jpn J Clin Oncol; 2015 Sep; 45(9):812-8. PubMed ID: 26117495
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study.
Twu NF; Ou YC; Liao CI; Chang WY; Yang LY; Tang YH; Chen TC; Chen CH; Chen TH; Yeh LS; Hsu ST; Chen YC; Chang CC; Cheng YM; Huang CY; Liu FS; Lin YS; Hsiao SM; Kan YY; Lai CH
Surg Oncol; 2016 Sep; 25(3):229-35. PubMed ID: 27566027
[TBL] [Abstract][Full Text] [Related]
32. [Isolated pelvic recurrences of cervical carcinoma treated with salvage chemoradiotherapy].
Besson N; Touboul E; Daraï É; Lefranc JP; Monnier L; Schlienger M; Huguet F
Cancer Radiother; 2014 Mar; 18(2):83-8. PubMed ID: 24462252
[TBL] [Abstract][Full Text] [Related]
33. Lack of any impact of histopathology type on prognosis in patients with early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Teke F; Yoney A; Teke M; Inal A; Urakci Z; Eren B; Zincircioglu SB; Buyukpolat MY; Ozer A; Isikdogan A; Unsal M
Asian Pac J Cancer Prev; 2014; 15(6):2815-9. PubMed ID: 24761906
[TBL] [Abstract][Full Text] [Related]
34. The Glasgow Prognostic Score Determined During Concurrent Chemoradiotherapy Is an Independent Predictor of Survival for Cervical Cancer.
Nishida T; Nakamura K; Haraga J; Ogawa C; Kusumoto T; Seki N; Masuyama H; Katayama N; Kanazawa S; Hiramatsu Y
Int J Gynecol Cancer; 2015 Sep; 25(7):1306-14. PubMed ID: 26067860
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
36. Influence of serum VEGF levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer.
Du K; Gong HY; Gong ZM
Asian Pac J Cancer Prev; 2014; 15(20):8793-6. PubMed ID: 25374209
[TBL] [Abstract][Full Text] [Related]
37. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
[TBL] [Abstract][Full Text] [Related]
38. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
Feng M; Zou J; Zhang Y; Sun L
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
[No Abstract] [Full Text] [Related]
39. Can pelvic lymphadenectomy be omitted in stage IA2 to IIB uterine cervical cancer?
Togami S; Kamio M; Yanazume S; Yoshinaga M; Douchi T
Int J Gynecol Cancer; 2014 Jul; 24(6):1072-6. PubMed ID: 24905616
[TBL] [Abstract][Full Text] [Related]
40. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
